Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blisibimod - Anthera Pharmaceuticals

Drug Profile

Blisibimod - Anthera Pharmaceuticals

Alternative Names: A-623; AMG-623; Blisibimod

Latest Information Update: 06 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Anthera Pharmaceuticals
  • Class Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended IgA nephropathy; Systemic lupus erythematosus
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 May 2018 Anthera Pharmaceuticals has patent protection for blisibimod in USA and Europe
  • 31 Mar 2018 Suspended - Phase-II for IgA nephropathy (Combination therapy, Treatment-experienced) in Spain, Sweden, Hungary, Italy, United Kingdom, Germany, Czech Republic, Thailand, Taiwan, Singapore, South Korea, Philippines, Malaysia, Hong Kong (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top